Morgan Stanley turns bearish on Novo Nordisk amid Semaglutide patent expiries
Morgan Stanley warned Novo Nordisk’s heavy reliance on Semaglutide could become a headwind as key patents begin to expire in the early 2030s.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.